Prime Medicine (PRME) stock

Genetic medicines , market cap $807M

Genetic medicines for diseases

Worth $807M

$4.35

-6.45%

As of 10:07 AM ET, delayed 15+ min · Live for Pro members

Why is PRME down?

Down 6.5% today, while its biotech peers are up 0.1%; no story names it yet.

Behind the market

Down 40% over three years while the S&P 500 rose 75%; up 11% in the past year.

Its share count rose 37.2% in a year, so each share is a smaller slice of the company.

Sources: Price history, Nov 6, 2026; Quarterly reports, Jun 30, 2026

Tell me next time PRME moves

Free account, no card. An optional alert when PRME moves or its score changes.

Or see it live, free for 24 hours. No account.

How the business stands and the timeline, for Pro members.

Quality Score

Below Average

In its industry

#116of 281

Biotech

Checks firing

5of 14

Trending up

From 52-week high

-26.4%

under its best in a year

PRME's Quality Score fell 1 point on Mon, Nov 9, to 1.

Follow PRME's trial news. Pro members can get an alert when Prime Medicine files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PRME files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“We expect to initiate our global Phase 1/2 study of PM577a in the second half of 2026…”Trial start · SEC filing · Aug 6

Cash$95.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into 2027”

Key facts on PRME

Key facts on PRME
Holding it back	37.2% more shares than a year ago from Massive's market data
Latest filing	10-Q, Aug 6 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind PRME's 1, free with an account →5 more reasons behind PRME's 1, for Pro members.

PRME in the news

TodayNo story names it yet.

Cash$95.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into 2027”

PRME catalysts

Coming up

After its last 4 reports it closed -7.7% on average, higher 0 of 4 times.

What's next for PRME, and how long its cash lasts

Next step the company has named

2H 2026“We expect to initiate our global Phase 1/2 study of PM577a in the second half of 2026 and to submit an IND and/or CTA for PM647 in the third quarter, with initial clinical data from both…”Trial start · SEC filing · Aug 6

What it means: when a trial begins, or reaches the stage the company named.

Lead program: PM647
Another trial: PM577aPhase 1/2 · Recruiting · 42 people · main data estimated Nov 2028 · NCT07748403

2 more trials, 2 more milestones and 33 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 2 quarters

$95.1M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2027” (8-K, Aug 6).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 7, 2025)
At-the-market share sales program (S-3ASR, filed Nov 7, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Allan Reine buys or sells

For Pro members: every trade, and Allan Reine’s 11 filings and quotes.

Get an alert when PRME files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why PRME scores 1

Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Persistence, and News.

What every line is worth, and the reason behind it, on PRME and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:07 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How PRME ranks in Biotech

PRME is #116 of 281 by Quality Score.

How PRME ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	PRAXPraxis Precision Medicines		Open for its score
	PRLDPrelude Therapeutics		Open for its score
	PROKProKidney		Open for its score
	PRQRProQR Therapeutics		Open for its score
116	PRMEPrime Medicine	5/14	1

Cash and short-term investments: PRME $95.1M, BEAM $1.15B.

When does PRME report earnings, and what happens after?

Expected to report Mon Nov 9, before the open (today).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What PRME reported on Aug 6, 2026

The quarter

The figures are not read from the release yet.

“The decrease in R&D expenses was driven primarily by fewer R&D personnel-related costs resulting from the workforce reduction announced in May 2025, and facility cost savings realized from bringing the Company’s vivarium in-house.”

The filing on EDGAR

Where the sales came from

PRME's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“We expect to initiate our global Phase 1/2 study of PM577a in the second half of 2026 and to submit an IND and/or CTA for PM647 in the third quarter, with initial clinical data from both programs anticipated in 2027.”

From its results filing (SEC filing · Aug 6)

1 more sentence, for Pro members.

The numbers

Market value: $807M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on PRME: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-9.2%-8.7%-4.2%

Mar 3May 7Aug 6

Reported	When	Gap	Reaction	5 days
Aug 6, 2026Before open	Before open	-0.7%	-4.2%	+3.9%
May 7, 2026Before open	Before open	0.0%	-8.7%	-4.1%
Mar 3, 2026Before open	Before open	-4.3%	-9.2%	-11.8%

PRME closed higher after 0 of its last 4 reports.

All 4 reports, and PRME's Quality Score going into each

Everyone reporting earnings this week

PRME sales and profit by year

Sales and profit by year

Sales grew in two of the last five years, to $4.6M in 2025. It lost money in each of the six years.

PRME has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on PRME, and all 14 on every stock.Get in free →

PRME RSI today: 53.1, above its 50-day and 200-day averages

Not scored

RSI 53.1, MACD below signal, above both averages. Not scored.13 readings

The deep dive on PRME

What it does and how it makes money3 findingsAn operating loss of $208M in fiscal 2025, on $4.63M of sales.Annual report, filed Mar 3, 2026"We are also eligible to receive more than $3.5 billion in milestones, including up to $185.0 million in preclinical milestones, up to $1.2 billion in development milestones and up to $2.1 billion in commercialization milestones, along with royalties on net sales." (10-K for fiscal 2025)SEC filing · Mar 3, 2026
Where it stands1 findingFor Pro members1 finding on where PRME stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"On April 18, 2025, the Company filed an arbitration demand with the AAA seeking a declaration that the Company’s AATD program is within our 'Field' as defined by the Beam Collaboration Agreement." (10-K for fiscal 2025)SEC filing · Mar 3, 2026A new heading in its "Risk Factors" this year: "The increasing use of social media platforms presents risks and challenges." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 3, 2026, against the one of Feb 28, 2025
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades PRME, for Pro members
Against its closest peers1 peerCash and short-term investments: PRME $95.1M, BEAM $1.15B.

6 more findings on PRME, each with its source, for Pro members.

PRME share count over time

37% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of PRME outstanding, as filed
Shares outstanding	As of
181.4M	Jul 31, 2026
180.6M	Apr 30, 2026
180.6M	Feb 20, 2026
180.5M	Oct 31, 2025

Offerings, shelves, and splits of PRME, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Nov 7, 2025
Raised $125.4M in a sale of shares, about 16% of its market value	Jul 31, 2025
Registered shares for a later sale (S-3)	Dec 13, 2024
Raised $120M in a sale of shares, about 15% of its market value	Feb 16, 2024

Which ETFs hold PRME?

In ETFs: PRME is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Prime Medicine

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

146 employeesCambridge, MAprimemedicine.com

What Prime Medicine says it competes with

“The development of genetic medicines is highly competitive and rapidly evolving, with multiple companies pursuing therapeutic approaches across gene editing, RNA-based therapies, and gene replacement modalities.”

From its annual report, SEC filing · Mar 3, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on PRME and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn PRME's score around: 9 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

See PRME's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: PRME's Quality Score is 1 (Below Average), #116 of 281 in Biotech.

What does PRME's Quality Score say?

PRME scores 1 today, which Breakaway calls Below Average. It is #116 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Down 40% over three years while the S&P 500 rose 75%; up 11% in the past year. Cash lasts about 2 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PRME's Quality Score?

PRME scores 1 today, which Breakaway calls Below Average (0 to 5). That is #116 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PRME's 1.

When does PRME report earnings?

Expected to report Mon Nov 9, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PRME closed higher after 0 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.